about
Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumorsIDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer CellsGemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patientsZidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.Nanotechnology in radiation oncology.Drug metabolism and homologous recombination repair in radiosensitization with gemcitabineDNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancerThe Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In VitroAntimetabolite Treatment for Pancreatic Cancer.Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage.Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating riskThe status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.Prospects in folate receptor-targeted radionuclide therapyImproving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a reviewRadiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation.Transport processes of radiopharmaceuticals and -modulators.Towards tailored therapy of glioblastoma multiforme.Hydroxyurea induced dermatomyositis-like eruption.New insights into the synergism of nucleoside analogs with radiotherapyEGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines.S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro.Ablation of experimental colon cancer by intratumoral 224Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy.The radiosensitizing effect of Paeonol on lung adenocarcinoma by augmentation of radiation-induced apoptosis and inhibition of the PI3K/Akt pathway.Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer.The role of apoptotic cell death in the radiosensitising effect of gemcitabine.Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinomaA single subexcitation-energy electron can induce a double-strand break in DNA modified by platinum chemotherapeutic drugs.Radionuclides in oncology clinical practice - review of the literature.Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer.
P2860
Q28474893-6650537D-4A7A-4447-A0BE-869E7DF1C2D1Q28551043-B3791572-4914-46D1-B558-6A5347D3FFFAQ33396393-B7507D6A-09DF-42EE-9554-DAAE914CCD3EQ34053519-8ED1018B-D56E-4298-A873-8148566A46DEQ34124280-0B99FB99-3590-49E5-AD6F-8A37D0EB741CQ35124554-0D6BFB4F-AA58-4A61-A2D8-075856F3E322Q35231578-5D2C92E9-95EA-4D6D-9132-5870C3C86FE0Q35600390-82CE94FD-D787-4B0E-8837-C96A2B534AEBQ35826334-15706C63-2CF0-474A-9D76-31EA22345BBBQ36341493-02621F6F-2E51-49F3-B9B4-1F714B1A9A40Q36736612-11AEA636-FFD7-445A-AE02-9D36E2D4504FQ37015715-0F5A82DF-4DE7-4A53-BC2B-74B5D567BB4BQ37033793-468532F1-B76A-4610-9C1D-AA1C7F2FFA43Q37193061-EA5E5723-B2B2-4520-8BF8-57210A83FC59Q37230970-AE7AFC20-BBEE-4936-A56D-615C31DDEDABQ37481367-7D268D94-20EF-4DE4-9022-0D163D41D1C4Q37697800-094623BF-62B5-4C88-8E67-48145029BA4BQ37797479-742EF4D4-4FAB-4E88-AC85-3413984A3E2DQ37885468-059D6F5C-26F9-4DCA-94EF-772155A59879Q37908815-E9B26E44-C88D-4DB2-B165-124F75178C22Q38033614-54F5E423-2E63-4549-8A50-D871461DFD4EQ38143241-82EBA4AA-A530-424F-96D5-60CD772C34E8Q38552978-540F0F17-D7E7-415A-BC42-5BB01B0A44D6Q38673319-E129752D-4E47-4AD5-8791-DB062778498FQ38728091-B883EBBD-C587-4BB3-8845-8C4885197A3EQ38805485-BFACF2F1-33DD-41E5-9078-4FEB10DFAD7BQ38960709-7E9B16B6-19D6-458B-BA88-0D1BBCB26571Q39122115-03239186-5B91-406B-B926-071196B42428Q39732460-AA71B40D-0FA2-4F30-94FD-7091EF356645Q39813658-B652BD6F-8068-4BA8-A481-6B0C9F9D1180Q41922693-A25DD751-D359-4033-8733-C179E710B1A6Q43198852-F3800C89-4624-49CA-A8FD-5CAF6F4EE844Q47916271-5A07B8D6-4468-4EB3-B242-70938742022AQ53812090-8B669F20-C20C-4EBA-AC04-6A6EC5BB8782
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antimetabolite radiosensitizers.
@en
type
label
Antimetabolite radiosensitizers.
@en
prefLabel
Antimetabolite radiosensitizers.
@en
P356
P1476
Antimetabolite radiosensitizers.
@en
P2093
Donna S Shewach
Theodore S Lawrence
P304
P356
10.1200/JCO.2007.11.5287
P407
P577
2007-09-01T00:00:00Z